

ARES ALLERGY HOLDINGS PLC



COMBINATION OF STALLERGENES AND GREER LABORATORIES:

ARES ALLERGY HOLDINGS PLC HAS SECURED AMF APPROVAL OF ITS PROSPECTUS FOR LISTING ITS SHARES ON EURONEXT PARIS

London (United Kingdom), 3 September 2015 – Ares Allergy Holdings Plc (“Ares Allergy”), today announces that it has secured visa n° 15-466 from the *Autorité des Marchés Financiers* (“AMF”) for its Prospectus regarding the listing of its shares on the Euronext Paris regulated market (“Euronext Paris”).

This Prospectus was prepared as part of the admission to trading on Euronext Paris of all the shares that will comprise the share capital of Ares Allergy upon completion of the merger through absorption of STALLERGENES S.A. by Ares Allergy.

STALLERGENES S.A. shares may be traded until 7 September 2015 included, date following which they will be delisted from Euronext Paris. Ares Allergy shares will be listed starting from the opening of the trading session on 8 September 2015.

The Prospectus is available on the company's websites at www.aresallergy.com and at www.stallergenes.com, at the company's registered office and on the AMF's website at www.amf-france.org.

Trading information:

Name: Stallergenes Greer

ISIN: GB00BZ21RF93 1 - Ticker: STAGR

ICB classification: 4577

Market: Euronext Paris regulated market

ABOUT ARES ALLERGY HOLDINGS PLC

Headquartered in London (UK), Ares Allergy is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and provision of allergy immunotherapy products and services. Ares Allergy is the parent company of Greer Laboratories, Inc. (whose registered office is in the U.S.) and will become the parent company of STALLERGENES S.A. (whose registered office is in France and which is listed on Euronext Paris) upon completion of the merger of STALLERGENES S.A. with and into Ares Allergy.

Contact:

UK: Robin Wrench, Brunswick Group
Email: waypoint@brunswickgroup.com
Tel. +44 (0)20 7404 5959

Forward-looking statements related to Ares Allergy Holdings Plc

This press release may contain forward-looking statements concerning the proposed combination and the benefits expected. Such statements are based upon the current beliefs and expectations of Ares Allergy Holdings Plc's management and are subject to risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. Ares Allergy Holdings Plc disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

Restrictions:

This document cannot be released directly or indirectly in South Africa, Australia, Canada, Japan, New Zealand or the United States of America. The information contained in this document does not constitute an offer to sell or the solicitation of an offer to buy or sell shares or other financial instruments in Ares Allergy Holdings Plc or Stallergenes S.A. in any jurisdiction, in particular in any jurisdiction in which such an offer, solicitation, purchase or sale would be illegal prior to the registration, exemption from registration or other qualification under the terms of legislation on financial instruments in such a jurisdiction. Persons in possession of this document are required to inform themselves about and comply with these restrictions. Neither Stallergenes S.A., nor Ares Allergy Holdings Plc or any other party to this transaction mentioned in this document accepts any liability in respect of persons who have obtained this document in violation of these restrictions. Shares in Ares Allergy Holdings Plc have not been and will not be registered under the US Securities Act of 1933 or under any other legislation of any jurisdiction in the United States of America.